These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1656 related items for PubMed ID: 14992487

  • 1. Changing strategies for the management of invasive fungal infections.
    Rapp RP.
    Pharmacotherapy; 2004 Feb; 24(2 Pt 2):4S-28S; quiz 29S-32S. PubMed ID: 14992487
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. The value of amphotericin B in the treatment of invasive fungal infections.
    Klepser M.
    J Crit Care; 2011 Apr; 26(2):225.e1-10. PubMed ID: 20951541
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Therapy of invasive organ mycoses in patients with systemic hematologic diseases].
    Karthaus M, Böhme A.
    Wien Med Wochenschr; 2001 Apr; 151(3-4):80-8. PubMed ID: 11789423
    [Abstract] [Full Text] [Related]

  • 7. Strategies for managing systemic fungal infection and the place of itraconazole.
    Potter M.
    J Antimicrob Chemother; 2005 Sep; 56 Suppl 1():i49-i54. PubMed ID: 16120634
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.
    Moen MD, Lyseng-Williamson KA, Scott LJ.
    Drugs; 2009 Sep; 69(3):361-92. PubMed ID: 19275278
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Voriconazole -- better chances for patients with invasive mycoses.
    Ghannoum MA, Kuhn DM.
    Eur J Med Res; 2002 May 31; 7(5):242-56. PubMed ID: 12069915
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Epidemiology and therapy of mycotic infections in immunocompromised host with special regard to the role of lipid formulations of amphotericin B].
    Viscoli C, Castagnola E.
    Recenti Prog Med; 1999 Oct 31; 90(10):545-57. PubMed ID: 10592741
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Evaluating prophylaxis of invasive fungal infections in patients with haematologic malignancies.
    Maertens J.
    Eur J Haematol; 2007 Apr 31; 78(4):275-82. PubMed ID: 17241370
    [Abstract] [Full Text] [Related]

  • 16. Antifungal treatment strategies in high risk patients.
    Rüping MJ, Vehreschild JJ, Cornely OA.
    Mycoses; 2008 Sep 31; 51 Suppl 2():46-51. PubMed ID: 18721331
    [Abstract] [Full Text] [Related]

  • 17. [New aspects in treatment of systemic mycoses].
    Presterl E, Graninger W.
    Wien Klin Wochenschr; 1998 Nov 13; 110(21):740-50. PubMed ID: 9871965
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Recent advances and challenges in the treatment of invasive fungal infections.
    Shao PL, Huang LM, Hsueh PR.
    Int J Antimicrob Agents; 2007 Dec 13; 30(6):487-95. PubMed ID: 17961990
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 83.